

# Metabolism Journal



Dear Friends and Colleagues,


As Editor-in-Chief of Metabolism: Clinical and Experimental, I'm excited with the prospects of our new collaboration with the WCIRDC and happy to share some great news about our journal.

Our impact factor has been continuously increasing over the past seven years that I have been serving at the helm, and is now at 5.963, placing the journal amongst the top 10% of endocrinology, diabetes, and metabolism journals as indexed in Journal Citation Reports\*. Similarly, cited half-life, or the duration an average paper continues receiving citations, has also increased significantly and is now in the top 10% of endocrinology, diabetes, and metabolism journals.

Please see relevant data in the tables below.

	Full Journal Title	Total Cites	Journal Impact Factor $\nabla$	Eigenfactor Score
16	<b>DIABETOLOGIA</b>	28,810	6.023	0.04800
17	<b>FREE RADICAL BIOLOGY AND MEDICINE</b>	40,089	6.020	0.04300
18	<b>DIABETES OBESITY &amp; METABOLISM</b>	8,680	5.980	0.02200
19	<b>METABOLISM-CLINICAL AND EXPERIMENTAL</b>	13,117	5.963	0.01700
20	<b>JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM</b>	78,047	5.789	0.10500
21	<b>ENDOCRINE-RELATED CANCER</b>	7,114	5.331	0.01200

	Full Journal Title	Journal Impact Factor	Cited Half-Life ▾
17	<b>AMERICAN JOURNAL OF PHYSIOLOGY- ENDOCRINOLOGY AND METABOLISM</b>	4.018	9.6
18	<b>INTERNATIONAL JOURNAL OF OBESITY</b>	5.159	9.5
18	<b>METABOLISM-CLINICAL AND EXPERIMENTAL</b>	5.963	9.5
20	<b>CLINICAL ENDOCRINOLOGY</b>	3.077	9.2
21	<b>ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA</b>	3.000	9.1
22	<b>JOURNAL OF NEUROENDOCRINOLOGY</b>	3.392	9.0
23	<b>DIABETIC MEDICINE</b>	3.132	8.9



This could not have happened without the dedication and expertise of the journal’s Editorial Board members as well its many reviewers and most importantly the authors of the papers we publish, to whom we are particularly thankful.

We are now committed to not only continue publishing studies on mechanisms underlying human pathology but to also prioritize the publication of translational research studies with important observations with direct clinical impact and most importantly high-quality clinical trials. Such papers should report novel diagnostics, novel medical therapies, or clinically relevant pathways or other major advances in the context of either interventional or observational studies in humans, that have the potential to change how we diagnose and/or treat our suffering fellow human beings or we translate new knowledge to important public health policies.

As we continue to improve and grow, I hope that you will consider submitting your best manuscripts for consideration.

We look forward to receiving your submissions and to working with you in the not so distant future.

With best regards,

Christos S. Mantzoros, MD, DSc, PhD h.c. mult.

Professor, Harvard Medical School